Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.
We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.
In November, 2014, we announced a merger with Copenhagen-based Ventac Partners. The combination of Lacerta Bio and Ventac Partners will dramatically increase the types of services we can offer our clients, as well as expand our geographic reach.
If you need assistance finding or assessing business development and/or partnership opportunities, contact us at email@example.com.
Lacerta Bio is seeking parenteral products for in-licensing on behalf of a US-based client. Key criteria are: Products which can be developed via the 505(b)(2) regulatory process in the US No specific therapeutic area Injectable could be infusion, prefilled syringe, or related presentation Products already approved outside the US are especially welcome Delivery / formulationRead More»
Lacerta Bio is looking to transact a business acquisition opportunity in the European injectables manufacturing sector. We are seeking manufacturing facilities which have the following criteria: Based in Western Europe EU approved manufacturing of parenteral products Could be a stand-alone company which manufactures its own products, or the divestment of a manufacturing facility owned byRead More»
Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? China is a large and growing opportunity for Western life science companies, as: Life Science in China is Booming – China’s life science industry has been growing at more than 20%+ per year, and is expect toRead More»
There is an interesting article in the current issue of The Journal of Precision Medicine on Alzheimer’s.
The article attempts to answer a seemingly simple, yet complex question…Can systems biology and precision medicine approaches be used to understand the disease better and develop more effective therapies?
First, a few of our highlights from the article:
First, while deaths from diseases such as breast cancer, heart disease, and stroke declined from 2000-2013, deaths attributed to Alzheimer’s skyrocketed by 71%.
Now interpreting these data can be tricky because of the limitations of recording deaths “with” dementia compared to deaths “from” dementia. Thus, while death certificates typically list acute diseases such as pneumonia, the underlying Alzheimer’s may not be recorded, resulting in an underreporting of the real data.
Second, the genetic risk factors associated with Alzheimer’s involve lipid transport, amyloid processing, inflammation, immunity, and other factors. Non-genetic factors include lifestyle, dietary, and other factors. So how do you treat such a complex situation, especially with mono therapy?
One approach is to use precision medicine-based approaches to create exquisitely specific subsegments of patients, and then tailoring the treatment approaches accordingly. This requires massive amounts of detail covering past medical histories, highly specific diagnostics, and so forth.
This obviously has significant implications for clinical development & trial design.
These complexities have led researchers to take a “systems biology” approach in order to discover drugs which target entire networks, as opposed to a single, individual pathway.
This leaves the door open to repurposing older drugs to target networks associated with Alzheimer’s. Indeed, the authors note that memantine was originally developed for the treatment of influenza.
The article is quite interesting, and anyone who wishes to learn more about the application of precision medicine and systems biology may learn a thing or two about these concepts.
Our friends at PharmaCircle recently published an interesting and provocative piece entitled Injectables: The New Oral? The PDF is available here. The article notes that, in 2014, seven of the top ten pharmaceuticals were parenteral products, with products such as Humira, Remicade, and Enbrel achieving $9-12+ billion in sales. This is a huge change from
How was Bio Europe in Stockholm last week? The Conference Itself – For us, the conference was terrific. We had nearly 30 high-quality meetings over the three days of partnering, plus more informal meetings and catch-ups at the receptions and dinners. As usual, we did not attend any of the company presentations or round-table discussions,
We’re late to the this party, but HBM Partners issued their two annual reports on M&A Activity and New Drug Approvals. Both reports also have Excel files with raw data for analysis. Below are a few highlights which caught our eye: M&A Activity – By numerous measures, 2015 was a record year, especially in terms